Dorin Todor

Dorin Todor

Auto-generated profile, based on publicly available information

Dorin Todor

Department of Radiation Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2005 in Medical Physics
Verified
Journal Article
Open access
JWJeffrey F. Williamson
Jeffrey F. Williamson
WBWayne Butler
Wayne Butler
LDLarry A. DeWerd
Larry A. DeWerd
MHM. Saiful Huq
M. Saiful Huq
GIGeoffrey S. Ibbott
Geoffrey S. Ibbott
DTDorin Todor
Dorin Todor
In March 2004, the recommendations of the American Association of Physicists in Medicine (AAPM) on the interstitial brachytherapy dosimetry using and were reported in Medical Physics [TG‐43 Update: Rivard et al., 31, 633–674 (2004)]. These recommendations include some minor changes in the dose‐calculation formalism and a major update of the dosimetry parameters for eight widely used interstitial brachytherapy sources. A full implementation of these recommendations could result in unintended changes in delivered dose without corresponding revisions in the prescribed dose. Because most published clinical experience with permanent brachytherapy is based upon two widely used source models, the Model 6711 and Model 200 sources, in this report we present an analysis of the dosimetric impact of the 2004 TG‐43 dosimetry parameters on the history of dose delivery for these two source models. Our analysis indicates that the currently recommended prescribed dose of 125 Gy for Model 200 implants planned using previously recommended dosimetry parameters [AAPM dose prescription: Williamson et al., Med. Phys. 27, 634–642 (2000)] results in a delivered dose of 120 Gy according to dose calculations based on the 2004 TG‐43 update. Further, delivered doses prior to October 1997 varied from 113 to 119 Gy for a prescribed dose of 115 Gy compared to 124 Gy estimated by the AAPM 2000 report. For implants using Model 6711 seeds, there are no significant changes (less than 2%). Practicing physicians should take these results into account when selecting the clinically appropriate prescribed dose for interstitial implant patients following implementation of the 2004 TG‐43 update dose‐calculation recommendations. The AAPM recommends that the radiation oncology community review this report and consider whether the currently recommended dose level (125 Gy) needs to be revised.

1 December 2014 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
LCLaurie W. Cuttino
Laurie W. Cuttino
DADouglas W. Arthur
Douglas W. Arthur
FVFrank Vicini
Frank Vicini
DTDorin Todor
Dorin Todor
TJThomas Julian
Thomas Julian
NMNitai Mukhopadhyay
Nitai Mukhopadhyay

29 May 2025 in Brachytherapy
Verified
Journal Article
Closed access
JCJunzo Chino
Junzo Chino
BEBeth Erickson
Beth Erickson
DGDavid Gaffney
David Gaffney
IHI-Chow Hsu
I-Chow Hsu
MKMitchell Kamrava
Mitchell Kamrava
EKElizabeth A Kidd
Elizabeth A Kidd

1 November 2019 in Brachytherapy
Verified
Journal Article
Closed access
CGChristopher L. Guy
Christopher L. Guy
EFEmma C. Fields
Emma C. Fields
BQBridget A. Quinn
Bridget A. Quinn
CFChristine M. Fisher
Christine M. Fisher
CLColton J. Ladbury
Colton J. Ladbury
DTDorin Todor
Dorin Todor


8 November 2024 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
ASAlexandra Stewart
Alexandra Stewart
CCC. Chargari
C. Chargari
ACA. Chyrek
A. Chyrek
FEF. Eckert
F. Eckert
JGJ.L. Guinot
J.L. Guinot
JHJ.M. Hannoun-Levi
J.M. Hannoun-Levi
Brachytherapy (BT) plays a key role in cancer treatment by delivering a high dose to a small volume over a short time. The use of BT is currently validated in a wide range of cancers such as cervical, prostate and breast cancers while being a favourable choice for organ preservation, such as in penile or rectal cancer, or in the setting of reirradiation. Consideration of the radiobiology of BT is integral to the choices made around dose and fractionation and combination with other techniques such as external beam radiotherapy (EBRT). Much of the radiobiology of brachytherapy is based on historic data, but fortunately there is a drive to integrate translational research including radiobiologic parameters into modern BT research. In a changing therapeutic landscape moving to a high dose rate (HDR) based on high dose per fraction, it is important to ensure that the incorporation of new radiobiology knowledge helps to drive clinical practice. This manuscript takes the ESTRO Brachytherapy pre-meeting course (May 3, 2024 - Glasgow ESTRO meeting) as a base and develops the concepts to present an overview of radiobiology in brachytherapy. Presented are 3 different considerations: the fundamentals of BT radiobiology (BT radiobiology history, biology and BT, α/β and re-irradiation), the pre-clinical radiobiology approach (pulsed dose radiotherapy (PDR) vs HDR, BT vs best EBRT techniques, high dose regions and integrated boost) and clinical radiobiology approaches (optimal number of BT fractions, radiobiology in BR for cervical, prostate, breast, skin/H&N and gastro-intestinal cancers). Presented is an analysis of radiobiology and modelling in BT aiding the integration of scientific pre-clinical and clinical data to allow a better understanding of the use of radioactive sources for cancer treatment.